Leaderboards/Renal cell carcinoma treatment

Renal cell carcinoma treatment

Last updated July 15, 2026

Rising Stars

Fresh ink, massive impact

Researchers

1
Chirag Krishna
Pfizer (United States)
2
Nicholas Salgia
Roswell Park Comprehensive Cancer Center
3
Jaleh Fallah
United States Food and Drug Administration
4
Divya Bezwada
Children's Medical Center
5
Abubaker Abdelrahman
University of KwaZulu-Natal
6
Renée Maria Saliby
Yale University
7
Bryan A. Nerger
Harvard University
8
Gilles Rademaker
University of Liège
9
Yuanyuan Qu
Fudan University Shanghai Cancer Center
10
Mao Yang
Shanghai Jiao Tong University

Papers

1
Mitochondrial complex I promotes kidney cancer metastasis
Nature|2024
114 cit.
2
Publication in Advanced Materials (2024) [78 citations, W4390608289]
Advanced Materials|2024
78 cit.
3
Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug Administration Pooled Analysis
Journal of Clinical Oncology|2024
74 cit.
4
Publication in Proceedings of the National Academy of Sciences (2024) [54 citations, W4403824346]
Proceedings of the National Academy of Sciences|2024
54 cit.
5
Update on Biomarkers in Renal Cell Carcinoma
American Society of Clinical Oncology Educational Book|2024
46 cit.
6
An immunogenetic basis for lung cancer risk
Science|2024
36 cit.
7
FDA Approval Summary: Belzutifan for Patients with Advanced Renal Cell Carcinoma
Clinical Cancer Research|2024
27 cit.
8
The influence of HLA genetic variation on plasma protein expression
Nature Communications|2024
16 cit.
9
Renal Cell Carcinoma of Variant Histology: New Biologic Understanding Leads to Therapeutic Advances
American Society of Clinical Oncology Educational Book|2024
15 cit.
10
Publication in Cancer Cell (2025) [15 citations, W4408290484]
Cancer Cell|2025
15 cit.

Emerging Leaders

Drafting the new consensus

Researchers

1
Giby V. George
Natera (United States)
2
Angela D. Motter
National Comprehensive Cancer Network
3
Angela Smith
University of North Carolina at Chapel Hill
4
Lucas Dennis
Foundation Medicine (United States)
5
Umberto Capitanio
Vita-Salute San Raffaele University
6
Lisa E. Hang
National Comprehensive Cancer Network
7
Saravana M. Dhanasekaran
University of Michigan
8
Russell W. Jenkins
Broad Institute
9
Elaine Guo Yan Chew
Nanyang Technological University
10
Michelle Mulan Lian
Nanyang Technological University

Papers

1
Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network|2022
655 cit.
2
NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022
Journal of the National Comprehensive Cancer Network|2022
398 cit.
3
Targeting TBK1 to overcome resistance to cancer immunotherapy
Nature|2023
167 cit.
4
NCCN Guidelines® Insights: Gastrointestinal Stromal Tumors, Version 2.2022
Journal of the National Comprehensive Cancer Network|2022
129 cit.
5
Head-to-head comparison of all the prognostic models recommended by the European Association of Urology Guidelines to predict oncologic outcomes in patients with renal cell carcinoma
Urologic Oncology Seminars and Original Investigations|2022
41 cit.
6
Observations that suggest a contribution of altered dermal papilla mitochondrial function to androgenetic alopecia
Experimental Dermatology|2022
39 cit.
7
A comprehensive assessment of frailty status on surgical, functional and oncologic outcomes in patients treated with partial nephrectomy—A large, retrospective, single-center study
Urologic Oncology Seminars and Original Investigations|2022
17 cit.
8
Exome sequencing in Asian populations identifies low-frequency and rare coding variation influencing Parkinson’s disease risk
Nature Aging|2024
15 cit.
9
TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids
Cancer Immunology Research|2025
15 cit.
10
Pancreatic metastases after surgery for renal cell carcinoma: survival and pathways of progression
World Journal of Urology|2022
11 cit.

Current Senior Leaders

Wrote the book, still writing it

Researchers

1
Toni K. Choueiri
Harvard University
2
Robert J. Motzer
Memorial Sloan Kettering Cancer Center
3
Paul Russo
Memorial Sloan Kettering Cancer Center
4
Bernard Escudier
Institut Gustave Roussy
5
Robert A. Figlin
Palmetto Hematology Oncology
6
Andrew C. Novick
Colorado School of Mines
7
Charles Swanton
The Francis Crick Institute
8
W. Marston Linehan
National Cancer Institute
9
Robert G. Uzzo
American Urological Association
10
Brian I. Rini
Vanderbilt University Medical Center

Papers

1
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
New England Journal of Medicine|2012
7.8k cit.
2
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
New England Journal of Medicine|2015
5.9k cit.
3
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
New England Journal of Medicine|2007
5.8k cit.
4
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
New England Journal of Medicine|2007
4.8k cit.
5
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
New England Journal of Medicine|2018
4.6k cit.
6
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
New England Journal of Medicine|2007
3.6k cit.
7
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
New England Journal of Medicine|2019
3.4k cit.
8
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
Science|2016
3.1k cit.
9
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
The Lancet|2008
3k cit.
10
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
New England Journal of Medicine|2019
2.5k cit.

Reagents for Renal cell carcinoma treatment

Citation-validated products used in this field

🔥 Trending

Gaining adoption fast

⭐ Top Rated

Best all-around

Cell Signaling TechnologyEvidence 64

CD74 (F6K1S) Rabbit Monoclonal Antibody

Cited in 10 papers
#70167$161,376
View Evidence →
Cell Signaling Technology

IGF-I Receptor alpha (D3A2W) Rabbit Monoclonal Antibody

Cited in 9 papers
#17174$161,351
View Evidence →
Santa Cruz BiotechnologyEvidence 61

BAP1 (C-4)

Cited in 8 papers
#sc-28383
View Evidence →

🌟 All-Time

Most validated

Cell Signaling Technology

MTA2 Antibody

Cited in 11 papers
#15793$317
View Evidence →
Cell Signaling TechnologyEvidence 66

Cleaved Caspase-3 (Asp175) Antibody (Alexa Fluor® 488 Conjugate)

Cited in 11 papers
#9669$493
View Evidence →
Proteintech

SIX2 Polyclonal antibody

Cited in 11 papers
#11562-1-AP
View Evidence →